About Neornat
CEO Message
Company Identity
NEORNAT Inc. develops first-in-class anti-cancer RNA drugs targeting functional RNAs and their specific regulators in cancer.
- The New RNA Therapeutics Company
- First-in-Class Target Therapeutics
History
2023
-
12
NEORNAT, Co., Ltd. completes investment attraction from Korea Technology Finance Corporation
-
12
NEORNAT Co., Ltd. signed an agreement with Liberi Group, a global consulting company, to transfer overseas technology and promote multinational joint development of NEORNAT's major assets.
-
11
Visit and inspection of WuxiAppTech, Neona Co., Ltd.’s IND carrying out CDMO agency
-
07
Signed a joint R&D agreement with Neona Co., Ltd. and Ceratgen Co., Ltd. for 'RNA-based liver cancer immunotherapy'
-
05
[Korea Angel Investment Association] Selected as a TIPS startup commercialization support project (US$ 80,000)
-
04
NEORNAT Co., Ltd. presents NRT-YHD_001 pipeline non-clinical results at the 2023 AACR at Florida, Olando, USA
-
04
National New Drug Development Agency, KDDF] New drug development project (non-clinical development part) final selection (support size, US$1.6 million ( / 2 years)
Macrophage activity-based liver cancer RNA immunotherapy NRT-YHD_001 IND Package completion and approval goal -
02
Signed a business agreement for IND approval of RNA-based anti-cancer drug NRT-YHD_001 with AIMSBiosciences Co., Ltd.
2022
-
11
Selected as Korea Angel Investment TIPS
-
09
Established NEORNAT affiliated R&D Center (2F, 47-3, Banpo-daero 39-gil, Seocho-gu, seoul, 06579 Korea )
-
06
Steintech Bio Season 1, Final Round Top 5 Selection and Best Company Selection
-
03
Completed pre-round Series A investment
-
02
Signed an MOU with Labgenomic for research and development of RNA-based anti-cancer drugs
2021
-
12
Catholic University Industry-University Cooperation Foundation- NEORNAT Inc. transfers 3 technologies for new drug development
-
12
NEORAT - AlgokBio signed an agreement to be the preferred bidder for liver cancer drug development
-
07
Selected as Korea Angel Investment TIPS
-
04
Selected as a 3-year project for the disease-centered translational research project
-
01
Shinhan Capital Investment Attraction
2020
-
11
Catholic University Industry-University Cooperation Foundation - Completed technology transfer for 4 cases of NEORNAT Inc.
-
10
Selected as K-BIC STAR (New drug development start-up company, Korea Health Industry Promotion Agency)
-
09
Completed attracting angel investment
Established NEORNAT Inc.
People
Founder, CEO & CTO Suk Woo Nam
- Professor, Department of Pathology, College of Medicine, The Catholic University of Korea (present)
- Director of Functional Rnomics Research Center, Catholic University of Korea (present)
- President, Basic Professors Association of College of Medicine, The Catholic University of Korea (Present)
- Sungkyunkwan University Department of Pharmacy, Master of Pharmacy, Doctor of Pharmacy
- Post-doctoral Fellow, Lab of Pathology, NCI, NIH, USA
- Senior Scientist, Genome Institute of Singapore, Singapore
- Published more than 254 SCI papers, and 28 patent applications and registrations
- Korea National Academy of Medicine Award for Basic Medicine (Pfizer Medical Award), 2014
- Minister of Health and Welfare Award, 2015
- Minister of Environment Award, 2013
- Served as a judge for the Ho-Am Award for Medicine
- Served as a judge for KOSDAQ technology special listing (RNA new drug part)
Director, NEORNAT Research Center Sungpil Yoon, Ph.D.
- Adjunct Research Professor, Functional Transcriptomics Research Center, The Catholic University of Korea (current)
- Ph.D., Wayne State University, USA
- Post-doctoral Fellow, NICHD, NIH, USA
- Senior Researcher, National Cancer Center
- Research Professor, Sungkyunkwan University, College of Pharmacy
- Published more than 80 SCI(E) papers, and 10 patent applications and registrations
- Research & Development Specialist in Anticancer Drug Combination-Therapy with Drug Repositioning
- Research & Development Specialist in Targeting Drug-Resistant or Poor Prognosis Cancer
- Research Specialist in Transcriptional Regulation Mechanisms
Head of Nonclinical Development Sang Yean Kim
- Team leader : non-clinical development of new drug candidates department (current)
- Ph.D., College of Medicine, The Catholic University of Korea
- Major in Tumor Biology
- Major in RNA Cancer Biology
- Major in Targeted-RNA therapy Development
- 7 SCI articles including Oncogene and 3 patent applications
- Modified mouse lung cancer analysis expert
- Responsible for the development of Macrophage RNA Immunotherapy
- Responsible for research and development of siRNA mix therapeutics
- Responsible for GLP-Tox and PK/PD assessment
Head of active and lead material development Min Jeong Na
- Team leader: new drug effective and leading substance development & verification department (current)
- Ph.D., College of Medicine, The Catholic University of Korea
- Major in Tumor Biology
- Major in DNA Repair & Cancer Biology
- Major in RNA Variation & Cancer
- 4 SCI articles including Experimental Molecular Medicine and 3 patent applications
- Real-time mouse liver cancer image analysis expert
- Responsible for the development of novel DNA repair enzyme-targeted therapy
- Responsible for non-clinical efficacy evaluation
Head of early cancer diagnosis development Jung Hwan Yoon
- Team leader: digestive cancer RNA drug development (current)
- Ph.D., College of Medicine, The Catholic University of Korea
- Major in Tumor Biology
- Experience in the early diagnosis and development of gastric cancer
- 50 SCI articles including Cancer Commun and 13 patent applications
- Gastric cancer early diagnosis kit development expert
- Specialist in the development of anticancer drugs targeting gastric cancer carcinogenesis
- Head of gastric cancer drug effective and lead material development and verification research
Collaborator
Domestic
Overseas
Contact Us
Headquarter
-
Address
#5104, Catholic Omnibus Park Building A, The Catholic Univ. of Korea Banpo-daero 222, Secho-gu, Seoul (06591)
-
TEL
02-2258-7308
-
FAX
02-537-6586
Research Center
-
Address
2F, 47-3, Banpo-daero 39-gil, Seocho-gu, Seoul (06579)
-
TEL
02-595-2812
-
FAX
02-595-2810